Study of AVZO-021 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05867251

Public ClinicalTrials.gov record NCT05867251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Study identification

NCT ID: NCT05867251
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Enrollment: 430 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 30, 2023 (Actual)
Primary completion: Jan 31, 2028 (Estimated)
Completion: Jan 31, 2030 (Estimated)
Last update posted: Sep 28, 2026

2023 – 2030

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Avenzo Therapeutics Recruiting Site	New Haven	Connecticut	06520	Recruiting
Avenzo Therapeutics Recruiting Site	Sarasota	Florida	34232	Recruiting
Avenzo Therapeutics Recruiting Site	Tampa	Florida	33612	Recruiting
Avenzo Therapeutics Recruiting Site	Mineola	New York	11501	Recruiting
Avenzo Therapeutics Recruiting Site	New York	New York	10016	Recruiting
Avenzo Therapeutics Recruiting Site	Cleveland	Ohio	44106	Recruiting
Avenzo Therapeutics Recruiting Site	Oklahoma City	Oklahoma	73117	Recruiting
Avenzo Therapeutics Recruiting Site	Portland	Oregon	97213	Recruiting
Avenzo Therapeutics Recruiting Site	Philadelphia	Pennsylvania	19107	Recruiting
Avenzo Therapeutics Recruiting Site	Dallas	Texas	75246	Recruiting
Avenzo Therapeutics Recruiting Site	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05867251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2026 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05867251 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →